Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Usana Health Sciences (USNA) over the last 15 years, with Q3 2025 value amounting to $100000.0.

  • Usana Health Sciences' Gains from Investment Securities rose 2658.23% to $100000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 2796.22%. This contributed to the annual value of $3.2 million for FY2024, which is 423.67% up from last year.
  • As of Q3 2025, Usana Health Sciences' Gains from Investment Securities stood at $100000.0, which was up 2658.23% from $24000.0 recorded in Q2 2025.
  • In the past 5 years, Usana Health Sciences' Gains from Investment Securities registered a high of $4.2 million during Q2 2022, and its lowest value of $24000.0 during Q2 2025.
  • Over the past 5 years, Usana Health Sciences' median Gains from Investment Securities value was $134000.0 (recorded in 2023), while the average stood at $1.0 million.
  • In the last 5 years, Usana Health Sciences' Gains from Investment Securities tumbled by 9082.01% in 2022 and then skyrocketed by 8809.52% in 2024.
  • Usana Health Sciences' Gains from Investment Securities (Quarter) stood at $2.9 million in 2021, then plummeted by 94.76% to $150000.0 in 2022, then dropped by 10.67% to $134000.0 in 2023, then plummeted by 44.78% to $74000.0 in 2024, then skyrocketed by 35.14% to $100000.0 in 2025.
  • Its Gains from Investment Securities stands at $100000.0 for Q3 2025, versus $24000.0 for Q2 2025 and $2.2 million for Q1 2025.